Table 4. Distribution and patterns of adverse drug reactions (ADR).
| n (%) | ||||||
| Type of ADRs | All ADRs (n = 979) | Severe ADRs (n = 99) | Zidovudine-related ADRs (n = 508) | Stavudine-related ADRs (n = 77) | Nevirapine-related ADRs (n = 143) | Efavirenz-related ADRs (n = 79) |
| Gastrointestinal: nausea,vomiting, abdominal pain | 155 (15.8) | 2 (2.0) | 137 (27.0) | 11 (14.3) | 23 (16.1) | 6 (7.6) |
| Anemia | 101 (10.3) | 30 (30.3) | 100 (19.7) | 1 (1.3) | _ | _ |
| Neutropenia | 80 (8.2) | 17 (17.2) | 80 (15.7) | _ | 1 (0.7) | _ |
| Thrombocytopenia | 21 (2.1) | 4 (4.0) | 20 (3.9) | 1 (1.3) | _ | _ |
| Hepatic: elevated liver enzymes± hyperbilirubinemia | 167 (17.1) | 13 (13.1) | _ | 115 (80.4) | 52 (65.8) | |
| Dermatological: rash | 62 (6.3) | 10 (10.1) | 2 (0.4) | 1 (1.3) | 43 (30.1) | 19 (24.1) |
| Dermatological: skin & nail hyperpigmentation | 86 (8.8) | _ | 86 (16.9) | _ | _ | _ |
| Central nervous system:headache, dizziness, insomnia | 82 (8.4) | 5 (5.1) | 41 (8.1) | 2 (2.6) | 2 (1.4) | 28 (35.4) |
| Peripheral neuropathy | 23 (2.3) | 4 (4.0) | _ | 23 (29.9) | _ | _ |
| Metabolic: dyslipidemia | 82 (8.4) | 9 (9.1) | 36 (7.1) | 39 (50.6) | 1 (0.7) | 13 (16.5) |
| Metabolic: lactatemia | 14 (1.4) | 2 (2.0) | _ | 13 (16.9) | _ | _ |
| Pancreatitis | 1 (0.1) | 1 (1.0) | _ | 1 (1.3) | _ | _ |
| Generalized: Fatigue,malaise, myalgia | 105 (10.7) | 2 (2.0) | 91 (17.9) | 5 (6.5) | 13 (9.1) | 4 (5.1) |